microsoft word - jad_casamitjana_et al.docx mri-bas screen preclin alzheim diseas prevent clinic trial adri casamitjanaa, paula petroneb, alan tucholkab, carl falconb,c, stavro skourasb, jo lui molinuevob,d,e, vernica vilaplanaa*, juan domingo gispertb,c*, alzheim diseas neuroimag initiativef author contribut equally. author affiliations: depart signal theori communications, universitat politcnica catalunya, barcelona, spain b barcelonaeta brain research center, pasqual maragal foundation. barcelona, spain. c centro investigacin biomdica en red bioingenieria, biomaterial y nanomedicina (ciber- bbn). spain d alzheim diseas cognit disord unit, hospit clnic, institut dinvestigacion biomdiqu august pi sunyer (idibaps), barcelona, spain. e ciber fragilidad y envejecimiento salud (ciberfes), madrid, spain. f data prepar articl obtain alzheim diseas neuroimag initi (adni) databas (adni.loni.usc.edu). such, investig adni contribut design implement adni and/or provid data particip analysi write report. complet list adni investig at: * correspond to: dr. juan domingo gispert barcelonabeta brain research centr - pasqual maragal foundat c/ wellington 30. 08005 barcelona, spain phone: +34 93 3160990 email: dr. veronica vilaplana depart signal theori communications, universitat politcnica catalunya c/ jordi girona 1-3, edifici d5 campu nord upc. 08034 barcelona, spain email: 2 abstract identif healthi individu harbor amyloid patholog constitut import challeng secondari prevent clinic trial alzheimer' disease. consequently, noninvas cost-effici techniqu detect preclin ad constitut unmet need critic importance. manuscript, appli machin learn structur mri (t1 dti) 96 cognit normal subject identifi amyloid-posit ones. model train public adni data valid independ local cohort. subject classif simul clinic trial setting, propos method abl save 60% unnecessari csf/pet test reduc 47% cost recruit simul clinic trial setting. recruit strategi capit acquir mri reduc overal invas pet/csf test prevent trials, demonstr potenti valu tool ad screening. protocol foster develop secondari prevent strategi ad. keywords: preclin alzheim disease, machin learning, clinic trial, secondari prevention, screening, amyloid patholog abbreviations: alzheim diseas (ad); alzheim diseas neuroimag initi (adni); cerebrospin fluid (csf); diffusion-tensor imag (dti); diffusion-weight imag (dti); function magnet reson imag (fmri); grei matter volum (gmv); logist regress (lr); mild cognit impair ad (mci-ad); normal control (nc); positron emiss tomographi (pet); precision-recal (pr); preclin stage ad (pread); receiver-oper curv (roc); region (rois); structur connect matrix (scm). 3 1 introduct alzheim diseas (ad) neurodegen diseas character progress loss cognit abil specif neuropatholog alterations, plaqu beta-amyloid (a) tangl tau proteins. decad seen paradigm shift ad perceiv biolog continuum rang wai normal cognit dementia [1]. new concept ad recogn presenc preclin stage ad (pread) preced symptomat phase mild cognit impair ad (mci-ad) dementia ad (ad). pread character cognit normal rang abnorm amyloid biomark measur cerebrospin fluid (csf) positron emiss tomographi (pet). studi amyloid biomark cognit healthi individu alter decad clinic diagnosi diseas and, therefore, pread stage constitut window opportun prevent therapi [2]. present, disease-modifi therapi fail adequ efficaci clinic trial grow consensu trial focu earlier stage disease, prompt treatment option irrevers neuron loss. example, a4 (anti-amyloid treatment asymptomat alzheim disease) stand secondari prevent trial aim prevent clinic symptom cognit healthi individu ad pathophysiology. however, prevent trial pread stage face crucial ethic logist challenges. considerations, slow buildup amyloid accumul requir long follow-up periods, larg amount individu screen order achiev adequ statist power small effect sizes. critic success ad prevent strategies, efficient, noninvas cost-effect method screen asymptomat at-risk subject prevent trial need developed. mri proven instrument character impend dementia cognit declin ad research clinic. structur chang ad-vulner structur entorhin cortex, hippocampu tempor lobe constitut diagnost marker cognit impair [3,4] stand valid marker ad progress [4]. moreover, mri modal (magnet reson spectroscopi [5], diffusion-weight imag (dwi) [6], diffusion-tensor imag (dti) [7,8]) function magnet reson imag (fmri) [9] offer 4 complementari inform unveil specif ad alter differ stage ad spectrum. hand, extent mri resolv structur connect chang preclin asymptomat stage ad area open explor [10,11]. machin learn field contribut batteri tool autom classif imag mri. tool appli publicli avail data resourc dedic ad biomark discovery. example, alzheim diseas neuroimag initi (adni)[12] primari goal test serial mri, pet biolog markers, combin clinic neuropsycholog assess measur progress mci earli ad. studi limit structur t1 data, recent effort cover imag modal (e.g. asl[13]), knowledge, machin learn effort focus diagnost categori (mci ad) predict impend cognit decline. recent review [14]. machin learn resolv signatur preclin ad remain investigated. furthermore, studi analyz practic util mri-bas screen recruit cognit normal volunt ad prevent trials. work, propos mri-driven machin learn protocol identif cognit normal individu bear abnorm amyloid level implement clinic trial recruitment. propos protocol, us mri-bas machin learn model identifi subject like report abnorm amyloid biomark (figur 1). replac gold standard measures, method gain knowledg acquir mris, minim pet csf tests, exchang non-invas cost-effect mris. assess util pread screen base mri. end, model train featur base brain morphometri structur connect subset adni cohort. then, local cohort valid capac model prospect detect amyloid- posit individuals. finally, determin benefit util classifi recruit subject secondari prevent trials. taken whole, result mri modal combin machin learn practic cost-effect screen tool ad 5 prevent trials. 2 materi method 2.1 subject csf t1 dti imag data 96 subject adni cohort [12] downloaded. subset adni select collect t1 dti imag acquir 3t scanner. sample, cognit normal subject classifi pread a42 csf concentr 192 pg/ml normal control (nc) else. threshold posit (a+) select optim discrimin control ad patient adni-independ autopsy-bas ad csf sampl analys multiplex xmap lumnex platform [shaw et al. ann neurol. 2009 apr; 65(4): 403413], mci ad classif criteria appli adni project report [17] refin exclus consid a+ individuals. classif criteria result 28 normal control (nc), 16 pread, 23 mci ad [mci], 29 ad. equival csf, t1 dti imag data acquir single-sit cohort ad unit hospit clinic barcelona (hcb) includ 87 subject (40 nc, 12 pre-ad, 21 mci ad [mci], 14 ad). subject classifi pread cognit normal a+, defin accord recommend refer valu innotest elisa (csf a42 < 500 pg/ml) [10,15,16]. criteria mci ad previous report [10] and, note, includ a+ patients. local ethic committe approv studi particip gave written inform consent. 2.2 imag acquisit process hcb particip underw mri 3t siemen triotim scanner provid 3d t1- weight imag follow parameters: repetit time (tr) = 2300 ms, echo time (te) = 2.98 ms, invers time (ti) = 900 ms, flip angl = 9, voxel resolut 111 mm3 240 sagitt slices; diffusion-weight sequences: tr = 7600 ms, te = 89 ms, flip angl = 90, 30 non-collinear direct (b = 1000 s/mm2) 1 non-gradi volum (b = 0), voxel size 2.052.052 mm3 60 6 axial slices. adni particip scan 3t ge mri model, 13 differ sites, compris 3d t1-weight images: tr = 7.256 ms, te = 2.988 ms, ti = 400 ms, flip angl = 11, voxel resolut 1.021.021.2 mm3 196 sagitt slices; diffusion-weight sequence: tr = 13000 ms, te = 69.1 ms, flip angl = 90, 41 non-collinear direct (b = 1000 s/mm2) 5 non-gradi images, voxel resolut 1.36721.36722.7 mm3 59 axial slices. t1-weight imag segment statist parametr map (spm) vbm8 toolbox [18] obtain csf, grai matter (gm), white matter (wm) probabilist map. then, binari gm mask form voxel probabl belong gm bigger probabl belong tissue. aal atla [19] montreal neurolog institut (mni) standard space warp subject t1 nativ space mean ant (upenn, uva uiowa, usa; dartel templat obtain segment step. aal map reslic t1 resolut nearest neighbour interpol intersect gm mask. volum aal region comput subject normal total intracrani volume, calcul sum csf, wm gm masks. structur connect matric (scm) computed. end, aal region superimpos dti data similar protocol describ above. tractography, creat seed mask insensit grei matter volum changes, interfac grei white matter dilat voxel. then, probabilist tractographi perform pair aal region fsl' probtrackx [20] (see detail [16]). 2.3 overview machine-learn method core machin learn pipelin train adni cohort dataset test local dataset hcb (figur 2). perform overal valid csf/pet biomark gold-standard. featur extract selection. featur select techniqu retriev reduc set inform featur high dimension medic images. t1-weight image, 7 extract 90-dimension vector correspond grei matter volum (gmv) 90 region (rois) describ aal atlas. dti image, extract 90x90 structur connect matrix (scm) atla roi (scm). upper triangular determin 4005- featur vector. differ acquisit protocol medic center introduc bias reflect consider variabl distribut imag featur vectors. thus, imag featur normal z-score comput independ cohort data compar ensur standard featur weights. differ filter featur select method compar performance. focus balanc relev redund subset featur method evalu purpose: f-test, mrmr-fcd mrmr-fcq [21]. provid optim perform select t1 dti imag featur respect study. discard us wrapper embed featur select method sensibl small sampl size result high gener error indic sever overfit train set. classification. cognit normal individu (nc pread) cohort train test classifi predict dichotom statu (either posit negative). adni cohort train classifi hcb data test. addition, differ classifi built, base t1 data and, one, base combin t1 dwi data. differ classif scheme test out, includ logist regress (lr), support vector machin (svm) linear gaussian kernels, random forest k-nearest neighbours, linear method (logist regress linear-svm) succesful, give similar result practice. finally, slightli better perform easier interpret model, binari lr classifi l2 regular penalti term , optim cross-valid strategi 8 adni cohort. lr classifi output score subject interpret probabl a+ a-, valid csf biomark readout. optim model test perform term save cost clinic trial recruitment. end, precis (fraction posit predict correctli classified)), recal (also known sensitivity, i.e. fraction posit instanc correctli classified) specif (fraction neg instanc correctli classified) calcul dichotom csf gold standard. precision-recal (pr) receiver-oper curv (roc) comput evalu method performance. formula appendix a. target normal popul mean ag 65, preval amyloid patholog estim 20% [2]. emploi bootstrap approach simul requir diseas preval iter repeat classif protocol, yield differ split test set run. secondari analysi sake compar previous report ad/mci classifiers, optim diagnost classifi deriv ident pipelin nc, mci ad subject cohort discrimin nc-mci nc-ad (for detail appendix b). finally, assess perform classifi optim discrimin pread nc classifi nc vs. diagnost categori (mci ad). savings. save clinic trial recruit calcul percentag differ resourc standard recruit protocol propos protocol mri-bas classifi (figur 1) obtain desir number pread subject clinic study. save assess term econom cost (equat [1]) particip burden (equat [2]) i.e. unnecessari pet/csf test spare mri-screening. eq. [1] eq. [2] term precis (p), recal (r), cost mri csf test estim cmri = 700, 9 cpet = 3000. cavg repres averag cost screen test includ addit cost (e.g. neuropsycholog cognit testing). simplicity, perform calcul sole imag costs. gener formul save structur formula provid appendic c & d. classifi threshold feature-extract method optim enhanc save eq.[1] visual precision-recal curves. 3 result report standard protocol data action train test cohort (section 3.1). then, evalu perform classifi base gmv t1-weight imag (section 3.2) extend classifi base combin t1 dti featur (section 3.3). demograph characterist studi sampl shown tabl 1. 3.1 data normal follow normal raw imag featur train cohort (adni) test cohort (hcb), result distribut z-score featur confirm match distribut kolmogorov-smirnov (ks) test (p <= 0.05) (figur 3). 3.2 classif pread subject t1-weight imag f-test select provid discrimin featur classif nc vs pread base adni data (figur 4, appendix d). classif algorithm provid rank weight featur (figur 4) base relevance. maxim area roc curv (auc) maxim clinic recruit save achiev 20 t1 featur (tabl 2). 3.3 classif pread subject multimod featur vector multimod classif perform combin imag featur t1 dti. z-score transform featur concaten modal yield 4095-dimension featur vectors. optim pr threshold yield highest save highli depend number featur 10 classifi (tabl 3, figur 5). featur select mrm-fcd [21] method result 45- dimension featur vector (featur list appendix d). notably, 2 45 inform featur t1 featur (featur 18: olfactori (l), featur 23: pallidum), 43 dti feature-pairs. result suggest dti featur inform t1 featur identifi preclin subjects. figur 5 show dti-connect regions, given weight sum dti-featur pair reflect relev identif pread. example, pallidum highlight roi multipl connect gmv feature. remarkably, perform (auc) cost save obtain t1 multimod classifi precis higher (p = 0.85) multimod model t1 case (p = 0.54) result larger save regard particip burden (76.5%). descript associ csf a42 level tractographi fall work describ [16]. 3.4 classif nc vs mci/ad subject t1-onli classifi optim discrimin nc mci/ad patient yield auc compar state-of-the-art method (auc>0.89). addit dti data margin improv classif perform (auc>0.91). again, metric achiev hcb cohort train classifi adni dataset. hand, classifi optim discrimin nc pread subject yield auc<0.20 discrimin nc diagnost categori (i.e. mci, ad). detail appendix c. 4 discuss work investig autom screen pread individu machin learn method featur deriv structur mri. present potenti integr technolog screen tool recruit subject secondari prevent trial present framework quantifi benefit approach econom particip burden terms. noteworthy, 11 propos replac gold standard pet/csf tests, provid predict amyloid posit order avoid unnecessari pet/csf test and, thus, reduc particip burden econom costs. valid cohorts. util public mri csf data avail adni featur select model training. independ hcb cohort serv model testing, simul real trial recruit scenario. data normal scheme enabl valid overcom differ data acquisit protocol scanner institutions. thus, relev model gener popul samples, differ ag educ ranges. note, perform algorithm stabl revers train test datasets. therefore, forese perform pread classif hold prospect appli independ cohort practic util pread screen purposes. featur selection. design, data-driven approach agnost previous report anatom chang ad. allow valid select featur given role preclin prodrom stage ad accord literature. expected, featur inform pread classif relat establish ad signature. case t1, characterist ad affect region includ atla roi hippocampu amygdala, tempor pariet area cingulum, thalamus, rectu fusiform giri (figur 4). region olfactori bulb pertain document alter olfactori pathogenesi ad dementia [22]. region show high discrimin power caudates, alter cognit normal individu high genet risk develop ad [23,24]. finally, role region globu pallidu clear pread (figur 5). explan atla roi includ nucleu basali meynert, adjac region explicitli identifi aal parcellation. previou voxelwis analysi hcb cohort, nucleu basali show alter pread [15] and, moreover, region consist report degener earli ad stage [25]. interestingly, featur classifi nc pread yield auc<0.2 discrimin nc diagnost categori (i.e. mci, ad). auc significantli depart 0.5 classifi facto. however, 0.5 12 suggest featur character pread nc appear opposit direct featur classifi nc vs ad. interpret reinforc fact classif model built ident pipelin train specif recogn diagnost categori perform accordingli report literatur (auc=0.95 20 t1 features, p=1.0, r=0.76), base mainli hippocamp tempor lobe volum (appendix b). futur work improv identif discrimin brain region voxelwis approach fulli character preclin ad signatur mri identifi overlap establish ad signatur [24]. overall, result show featur select priorit dti featur t1 featur multimod imag vector. thus, dti feature-pair robust t1 features, compens lower imag qualiti (resolution, noise, blur) artifact given surrog measur brain anatom connect dti. also, dti convei complementari inform white matter connectivity. data rais question chang connect evid earli ad volumetr chang [16]. nevertheless, relev dti t1 featur observ studi confirm datasets. despit similar performance, multimod model precis t1-base model, translat fals posit unnecessari pet/csf test exchang mri scan given low recal model. rang applic pread prevalence. proof-of-concept study, mri-bas classifi threshold optim maxim cost savings. model tune applic minim particip burden (equat 2). practic util mri-bas screen protocol highli depend preval pread subjects, turn, intim relat ag rang ag distribut clinic study. lower diseas prevalence, save reli higher classifi precis mri-bas screen layer worthwhil (equat 1). propos recruit protocol effici 13 younger cohort best suit secondari intervent trials. precis vs. recall. higher classifi precis reduc number unnecessari pet/csf acquisit (less false-positives). higher classifi recal reduc size initi particip pool mri imag need acquir limit fals neg miss classification. ensur cognit healthi particip pool incur associ cost (e.g. addit cognitive/clin tests) scale number participants. true mri-bas screen reli recruit larger initi cognit healthi particip pool mri scan cognit tests, estim propos protocol effici term save econom particip burden (see appendix c detail complex save structure). exampl application. standard clinic trial recruit protocol, preval pread 20%, 1500 individu need undergo csf/pet test order identifi 300 a+ subjects. first, preliminari mri scan acquir exclud particip displai incident find neuroradiolog exclus criteria. instead, modest mri-bas classifi (0.54 precision/0.84 recall), requir 1807 mri imag predict ident pool 300 posit individuals. images, 555 predict posit sent csf/pet validation, 300 result true posit 255 fals positives. second protocol spare 945 pet/csf tests, exchang addit 307 mri requir compens fals neg miss classifier. econom terms, save provid mri-screen layer prevent 60% unnecessari pet/csf scan save 47% cost compar standard protocol reli gold standard csf/pet measures. comparison approach detect a. present, blood-bas approach detect a+ activ pursu (nakamura et al. natur volum 554, page 249254 (08 februari 2018) doi:10.1038/nature25456; ovod et al. alzheim dement. 2017 aug;13(8):841-849; naber et al. embo mol med. 2018 may;10(5). method high concord (aucs~0.80-0.90) plasma speci pet imaging. unlik pread group includ 14 cognit normal subjects, perform method estimati includ mci and/or ad patient favour them. nevertheless, work demonstr link cerebr peripher alter and, valid automated, repres major resourc screen gener popul implement secondari ad prevent strategies. hand, mri-bas approach particularli us context research studi csf pet imag envisaged, case mri scan typic prescrib safeti reasons. limitations. main limit studi small sampl size studi groups. limit avail t1 dti data individu cohorts. nevertheless, previou report standard evalu algorithm computed-aid diagnosi dementia base structur mri recommend small train set (n~30) mimic clinic set limit data avail avoid overtrain issu [bron et al. neuroimage. 2015 1;111:562-79]. hand, maxim generaliz perform evaluations, priorit appli algorithm independ dataset differ demograph scan parameters. base rationale, prioritis test algorithm independ cohort total sampl size. nevertheless, futur studi focu valid similar approach larger test set better account sampl demograph confounders. end, given result report, t1 data sole achiev similar level classif accuracy. addition, small sampl size limit complex machin learn scheme implement robustly. futur studi bigger sampl size allow investig potenti improv classif perform complex classifi schemes. nevertheless, consid report promis proof-of-concept as, simpl logist regress model, robust perform achiev independ dataset distinct demograph characteristics, potenti lead signific save gold-standard procedures. limit experiment approach threshold a+ complet equival cohorts. respect csf cut-off independ valid 15 yield optim discrimin nc ad patient respect analyt platform (innotest elisa hcb xmap-luminex adni). absolut valu definit comparable, correl shown high (r > 0.75 [irwin et al arch neurol. 2012 aug; 69(8): 10181025; wang et al. j alzheim dis. 2012; 31(2): 439445, fagan et al. arch neurol. 2011 sep; 68(9): 11371144.]). nevertheless, accord publish convers equations, respect threshold interlaboratori reproduc analyt platform fall rage 15-30% (%cv) [kang clin chem. 2013 jun; 59(6): 903916.]. base rationale, prefer us publish valid cut-off compar previou report respect datasets. similar limit aris equat posit base csf pet data cut-off defin modalities, like hansson et al alzheim dement. 2018 mar 1. pii: s1552-5260(18)30029-3. doi: 10.1016/j.jalz.2018.01.010. futur developments. studi restrict limit subject sampl model recogn limit aspect pread signature. expect enhanc perform larger train sets. adopt atla roi-bas approach aal atla implement coars parcellation; futur work explor addit fine-grain atlas explor voxel-bas multivari approaches. despit modest performance, model appli prospect classif independ cohort. follow-up effort involv applic workflow larger imag dataset acquir alfa project [25]. line improv predict actual csf a42 level order dichotom result later stage order accommod optim a42 threshold differ applications. 5 conclus proof-of-concept study, establish machin learn detect amyloid patholog cognit normal popul t1 dti mri. method prospect pread screen subject futur cohorts, follow appropri data standardization. approach lead signific reduct particip burden econom costs. propos applic meant replac gold-standard techniqu determin amyloid pathology. 16 indeed, benefit method reli ad valu mri imag acquired, prior pet scan secondari prevent trials. near future, ought explor biomark (p-tau, t-tau) risk factor (apoe4, app) relationship multimod imag featur identif preclin ad. taken together, mri-bas pread detect valuabl tool secondari prevent trial valid prospect multicent clinic trials. 17 6 acknowledg pp thank grgori operto raffael cacciagglia insight comments. work partial support project biggraph-tec2013-43935- r malegra tec2016-75976- r financ spanish ministerio economa y competitividad european region develop fund (erdf). ac support spanish ministerio educacin, cultura y deport fpu research fellowship. juan d gispert hold ramn y cajal fellowship (ryc-2013 13054). data collect share project fund alzheimer' diseas neuroimag initi (adni) (nation institut health grant u01 ag024904) dod adni (depart defens award number w81xwh-12-2-0012). adni fund nation institut aging, nation institut biomed imag bioengineering, gener contribut following: abbvie, alzheim association; alzheim drug discoveri foundation; araclon biotech; bioclinica, inc.; biogen; bristol- myer squibb company; cerespir, inc.; cogstate; eisai inc.; elan pharmaceuticals, inc.; eli lilli company; euroimmun; f. hoffmann-la roch affili compani genentech, inc.; fujirebio; ge healthcare; ixico ltd.; janssen alzheim immunotherapi research & development, llc.; johnson & johnson pharmaceut research & develop llc.; lumosity; lundbeck; merck & co., inc.; meso scale diagnostics, llc.; neurorx research; neurotrack technologies; novarti pharmaceut corporation; pfizer inc.; piram imaging; servier; takeda pharmaceut company; transit therapeutics. canadian institut health research provid fund support adni clinic site canada. privat sector contribut facilit foundat nation institut health (www.fnih.org). grante organ northern california institut research education, studi coordin alzheim therapeut research institut univers southern california. adni data dissemin laboratori neuroimag univers 18 southern california. 7 disclosur statement author conflict report 8 refer [1] sperl ra, aisen ps, beckett la, bennett da, craft s, fagan am, et al. defin preclin stage alzheim disease: recommend nation institut aging-alzheim associ workgroup diagnost guidelin alzheim disease. alzheim dement 2011;7:28092. doi:10.1016/j.jalz.2011.03.003. [2] jansen wj, ossenkoppel r, knol dl, tijm bm, schelten p, verhei frj, et al. preval cerebr amyloid patholog person dementia: meta- analysis. jama 2015;313:192438. doi:10.1001/jama.2015.4668. [3] frisoni gb, fox nc, jack cr, schelten p, thompson pm, thompson pm. clinic us structur mri alzheim disease. nat rev neurol 2010;6:6777. doi:10.1038/nrneurol.2009.215. [4] racin am, adluru n, alexand al, christian bt, okonkwo oc, oh j, et al. associ white matter microstructur amyloid burden preclin alzheim disease: multimod imag investigation. neuroimag clin 2014;4:60414. doi:10.1016/j.nicl.2014.02.001. [5] graff-radford j, kantarci k. magnet reson spectroscopi alzheim disease. neuropsychiatr di treat 2013;9:68796. doi:10.2147/ndt.s35440. [6] clerx l, visser pj, verhei f, aalten p. new mri marker alzheim disease: meta-analysi diffus tensor imag comparison medial tempor lobe measurements. j alzheim di 2012;29:40529. doi:10.3233/jad-2011-110797. [7] prescott jw, guidon a, doraiswami pm, roi choudhuri k, liu c, petrella jr, et al. alzheim structur connectome: chang cortic network topolog increas amyloid plaqu burden. radiolog 2014;273:17584. doi:10.1148/radiol.14132593. [8] nir tm, jahanshad n, villalon-reina je, toga aw, jack cr, weiner mw, et al. effect region dti measur distinguish alzheim disease, mci, normal aging. neuroimag clin 2013;3:18095. doi:10.1016/j.nicl.2013.07.006. [9] filippi m, agosta f. structur function network connect breakdown alzheim diseas studi magnet reson imag techniques. j alzheim di 2011;24:45574. doi:10.3233/jad-2011-101854. [10] molinuevo jl, ripol p, sim m, llad a, oliv j, balasa m, et al. white matter chang preclin alzheim disease: magnet reson imaging-diffus tensor imag studi cognit normal older peopl posit amyloid 19 protein 42 levels. neurobiol ag 2014;35:267180. doi:10.1016/j.neurobiolaging.2014.05.027. [11] chtelat g, la joie r, villain n, perrotin a, la sayett v, eustach f, et al. amyloid imag cognit normal individuals, at-risk popul preclin alzheim disease. neuroimag clin 2013;2:35665. doi:10.1016/j.nicl.2013.02.006. [12] adni | alzheim diseas neuroimag initi n.d. (access juli 13, 2017). [13] collij le, heeman f, kuijer jpa, ossenkoppel r, benedictu mr, mller c, et al. applic machin learn arteri spin label mild cognit impair alzheim disease. radiolog 2016;281:86575. doi:10.1148/radiol.2016152703. [14] falahati f, westman e, simmon a. multivari data analysi machin learn alzheim diseas focu structur magnet reson imaging. j alzheim di 2014;41:685708. doi:10.3233/jad-131928. [15] gispert jd, rami l, snchez-benavid g, falcon c, tucholka a, roja s, et al. nonlinear cerebr atrophi pattern alzheim diseas continuum: impact apoe4 genotype. neurobiol ag 2015;36:2687701. doi:10.1016/j.neurobiolaging.2015.06.027. [16] tucholka a, grau-rivera o, falcon c, rami l, snchez-val r, llad a, gispert jd, molinuevo jl, alzheim diseas neuroimag initiative. structur connect alter ad continuum: reproduc independ sampl correl csf tau. j alzheim dis. 2018;61(4):1575-1587. doi: 10.3233/jad-170553. [17] jack cr, albert ms, knopman ds, mckhann gm, sperl ra, carrillo mc, et al. introduct recommend nation institut aging-alzheim associ workgroup diagnost guidelin alzheim disease. alzheim dement 2011;7:25762. doi:10.1016/j.jalz.2011.03.004. [18] spm - statist parametr map n.d. (access juli 13, 2017). [19] tzourio-mazoy n, landeau b, papathanassi d, crivello f, etard o, delcroix n, et al. autom anatom label activ spm macroscop anatom parcel mni mri single-subject brain. neuroimag 2002;15:27389. doi:10.1006/nimg.2001.0978. [20] jenkinson m, beckmann cf, behren tej, woolrich mw, smith sm. fsl. neuroimag 2012;62:78290. doi:10.1016/j.neuroimage.2011.09.015. [21] hanchuan peng h, fuhui long f, ding c. featur select base mutual inform criteria max-dependency, max-relevance, min-redundancy. ieee tran pattern anal mach intel 2005;27:122638. doi:10.1109/tpami.2005.159. [22] kate m, sanz-arigita ej, tijm bm, wink am, clerigu m, garcia-sebastian m, et al. impact apoe-4 famili histori dementia grei matter atrophi cognit healthi middle-ag adults. neurobiol ag 2016;38:1420. doi:10.1016/j.neurobiolaging.2015.10.018. 20 [23] groth m, heinsen h, teipel sj. atrophi cholinerg basal forebrain adult ag rang earli stage alzheim disease. biol psychiatri 2012;71:80513. doi:10.1016/j.biopsych.2011.06.019. [24] dickerson bc, bakkour a, salat dh, feczko e, pacheco j, greve dn, et al. cortic signatur alzheim disease: region specif cortic thin relat symptom sever mild mild ad dementia detect asymptomat amyloid-posit individuals. cereb cortex 2009;19:497510. doi:10.1093/cercor/bhn113. [25] molinuevo jl, gramunt n, gispert jd, fauria k, estel m, minguillon c, et al. alfa project: research platform identifi earli pathophysiolog featur alzheim disease. alzheim dement transl re clin interv 2016;2:8292. doi:10.1016/j.trci.2016.02.003. 21 tabl 1 - demograph biomarkers, hcb adni separately, hcb adni merg together. * significantli differ vs. control group (p < 0.05). significantli differ vs. preclin group (p < 0.05). significantli differ vs. group hcb popul (p < 0.05). groups: nc- normal controls, pre- preclinicals, mci- mild cognit impair ad, ad- alzheim diseas patients. hcb adni nc pre mci ad nc pre mci ad n 40 12 21 14 28 16 23 29 n total 87 96 women/men 26/14 7/5 10/11 8/6 15/13 10/6 7/16 11/18 w=51, m=36 w=43, m=53 mean ag 62.1 72.7* 70* 65.9 71.8 75.8* 72.4 74.2 sd 8.5 6 7.5 9 5.1 4.6 8 7.8 mean schol. 11.9 10.6 11 8.6* 17.2 16.2 16.1 15.2* sd 4.4 4 4.3 4.2 2.6 2.1 2.8 2.8 apoe4 car. 9 4 10 8 7 8 21 20 non-carri 31 8 10 6 21 8 2 9 mean 760.8 375.8 339.1 310.7 239 148.5 135.7 130 sd 160.3 80.1 71.9 83.9 25.7 24.1 20.7 23.1 mean p-tau 56.6 76.6 112.2 105.7 31.2 51.7 52.9 66.6 sd 27.7 47.8 43.7 43 12.2 32.9 18.7 43 22 nc vs pread featur auc precis recal savings% (cost) savings% (csf/pet) 10 0.65 0.48 0.75 40.9 58.3 20 0.76 0.54 0.83 47.1 62.9 30 0.70 0.37 0.83 33.4 45.9 40 0.65 0.42 0.66 32.7 52.3 50 0.61 0.36 0.58 22.3 44.4 tabl 2: perform pread classif model accord number featur select (10, 20, 30, 40, 50). classif nc vs pread, optim perform (auc = 0.76) achiev 20 featur optim p-r threshold produc highest save highlighted. 23 nc vs pread featur auc precis recal savings% (cost) savings% (csf/pet) 10 0.70 0.41 0.68 32.6 51.2 20 0.65 0.60 0.59 40.9 66.6 30 0.70 0.54 0.59 37.9 62.9 40 0.69 0.83 0.51 43.3 75.9 45 0.69 0.85 0.60 49.3 76.5 50 0.70 0.66 0.60 43.8 69.7 tabl 3: perform classif accord number featur select (10, 20, 30, 40, 45, 50). optim perform (auc = 0.69) provid 45 features. optim pr threshold produc highest save list (savingscost = 49%, savingscsf/pet = 76.5%). 24 figur 1: outlin clinic recruit protocol subject pread pathophysiology. (a) standard recruit protocol clinic trials. (b) propos protocol mri-bas machin learning. standard protocol, cognit healthi particip undergo mri scan identifi radiolog exclus criteria (e.g. cerebrovascular disease). cognit healthi subject brain injuri particip pet/csf test, fraction posit determin diseas prevalence. propos protocol add exclus layer autom mri-bas classif predict subset pread subject later subject pet/csf acquisition. case, target cohort defin true posit rate (tp%) classif algorithm. initi particip pool need larger propos protocol classifi fals neg excluded. 25 figur 2: core model train valid autom mri-bas classif a-posit (a+) subject logist regression. adni dataset model training. featur extract gmv roi follow featur select dimension reduction. paramet model optim iter base train data maxim perform measur term area receiver-oper characterist curv (roc). final model test hbc dataset predict a+ subject valid csf biomark ground truth. model predict perform assess term area roc overal save produc altern recruit scenario includ mri-bas classification. 26 figur 3. exampl distribut t1 featur gmv roi (a) (b) z- score normalization. adni hbc cohort distribut shown red blue respectively. 27 figur 4: (a) roi featur select best perform method (f-test, 20 features). (b) rank list inform featur accord weight provid lr decis function (adni cohort). (c) roc analysi method perform 10, 20, 30 rank featur base valid cohort (hcb). (d) savingscost function precision-recal calcul base optim number featur (n = 20) appli hcb cohort. color scale dash contour line indic savings. particular, contour line savings= 0.001 demark boundari area precision-recal curv save > 0. optim pr threshold provid highest save (p = 0.54, r = 0.83, save = 47%). horizont dot line p=0.2 denot save random classifier, note precis valu equal preval pread population. 28 figur 5: (a) exampl roi dti connect pallidum feature-pair multimod vector machin learning. (b) rank list connect roi accord weight sum featur scm matrix base train set adni. weight provid lr decis function. (c) roc analysi method perform 30, 44, 55 rank featur multimod t1+dti featur vector base valid dataset hcb. (d) savingscost function precision-recal calcul base optim number featur (n = 45) calcul valid dataset hcb. color scale dash contour line indic savings. contour line savings= 0.001 demark boundari meaning area precision-recal curv savings= 0. optim p vs r pair provid highest save (p = 0.85, r = 0.60, savingscost = 49%). horizont dot line p=0.2 denot save random classifier.